Beta

Exozymes, inc.EXOZ.US Overview

US StockHealthcare
(No presentation for EXOZ)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

EXOZ AI Insights

EXOZ Overall Performance

EXOZ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EXOZ Recent Performance

-2.59%

Exozymes, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

EXOZ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check EXOZ's Trend

EXOZ Key Information

EXOZ Valuation Metrics

EXOZ Profile

eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

Price of EXOZ

EXOZ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EXOZ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
25.70
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
25.70
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is EXOZ's latest earnings report released?

    The most recent financial report for Exozymes, inc. (EXOZ) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EXOZ's short-term business performance and financial health. For the latest updates on EXOZ's earnings releases, visit this page regularly.

  • How much debt does EXOZ have?

    As of the end of the reporting period, Exozymes, inc. (EXOZ) had total debt of 1.24M, with a debt ratio of 0.21. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EXOZ have?

    At the end of the period, Exozymes, inc. (EXOZ) held Total Cash and Cash Equivalents of 3.04M, accounting for 0.51 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is EXOZ's EPS continuing to grow?

    According to the past four quarterly reports, Exozymes, inc. (EXOZ)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EXOZ?

    Exozymes, inc. (EXOZ)'s Free Cash Flow (FCF) for the period is -2.05M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 65.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EXOZ?

    The latest valuation data shows Exozymes, inc. (EXOZ) has a Price-To-Earnings (PE) ratio of -6.76 and a Price/Earnings-To-Growth (PEG) ratio of -0.46. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.